文献速递食管胃疾病与幽门螺杆菌消化内镜消化道肿瘤与早癌

内镜切除后pMM/SM1食管癌长期结局:多中心前瞻性队列研究

Long-Term Outcomes After Endoscopic Resection for pMM/SM1 Esophageal Cancer: A Multicenter Prospective Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2026-10-26

这项多中心前瞻性队列纳入385例内镜切除后病理诊断为pMM/SM1的食管癌患者(315例鳞癌,70例腺癌)。鳞癌5年总生存率92.3%,腺癌94.2%;无淋巴血管侵犯且未追加治疗者5年生存率鳞癌94.0%、腺癌93.3%。提示监测对多数LVI阴性病例是合理选择。

要点

  • pMM/SM1食管癌内镜切除后长期生存良好,鳞癌5年OS 92.3%、腺癌94.2%。
  • LVI阴性未追加治疗者5年生存率鳞癌94.0%、腺癌93.3%。
  • LVI阴性鳞癌中0-II型且≤30mm者转移复发率低(2.9%)。

核心结论

  • 内镜切除后pMM/SM1食管癌与极好的长期生存相关,监测对多数LVI阴性病例是合理选择,但部分高危患者可考虑追加治疗。

研究设计与样本

  • 多中心前瞻性队列研究,纳入内镜切除后病理诊断为pMM/SM1的鳞癌或食管腺癌患者,共385例(鳞癌315例,腺癌70例)。

主要发现

  • 鳞癌5年总生存率92.3%(95%CI 88.8%-94.8%),腺癌94.2%(95%CI 85.4%-97.8%)。
  • LVI阴性未追加治疗者5年生存率鳞癌94.0%(95%CI 90.2%-96.4%),腺癌93.3%(95%CI 83.5%-97.5%)。
  • LVI阴性鳞癌累积转移复发率pMM为6.3%(95%CI 3.0%-12.6%),pSM1为10.5%(95%CI 2.6%-33.7%);腺癌分别为2.2%(95%CI 0.3%-13.9%)和0.0%(95%CI无法计算)。
  • LVI阴性鳞癌中,0-II型且≤30mm病变累积转移复发率低至2.9%(95%CI 1.1%-7.5%)。
  • 第二原发食管癌5年累积发生率鳞癌25.8%,腺癌3.6%。

临床怎么用

  • 对LVI阴性的pMM/SM1食管癌患者,监测可作为合理管理策略。
  • 对LVI阴性鳞癌中0-II型且≤30mm的低危病变,转移复发风险低,支持监测。
  • 对选定的高危患者可考虑追加治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The optimal management of esophageal cancer with muscularis mucosae or shallow submucosal invasion (postendoscopic resection [ER] pMM/SM1 cancer) remains controversial. Evidence is largely retrospective, and prospective data are lacking. METHODS: This study enrolled patients with squamous cell carcinoma (SCC) or esophageal adenocarcinoma (EAC) diagnosed as post-ER pMM/SM1 cancer. Outcomes included overall survival, metastatic recurrence, local recurrence, and second primary esophageal cancer. RESULTS: Overall, 385 patients were enrolled, including 315 with SCC and 70 with EAC. Five-year overall survival was 92.3% (95% Confidence interval [CI], 88.8%-94.8%) for SCC and 94.2% (95% CI, 85.4%-97.8%) for EAC. Among post-ER lymphovascular invasion (LVI)-negative patients managed without additional treatment, 5-year survival rates were 94.0% (95% CI, 90.2%-96.4%) for SCC and 93.3% (95% CI, 83.5%-97.5%) for EAC. Cumulative metastatic recurrence rates for LVI-negative SCC were 6.3% (95% CI, 3.0%-12.6%) for pMM and 10.5% (95% CI, 2.6%-33.7%) for pSM1 disease, whereas corresponding rates for EAC were 2.2% (95% CI, 0.3%-13.9%) and 0.0% (95% CI could not be calculated). In LVI-negative SCC, lesion size and macroscopic appearance were independent predictors of metastatic recurrence: type 0-II lesions ≤30 mm had a low cumulative metastatic recurrence rate of 2.9% (95%CI, 1.1%-7.5%). The 5-year cumulative incidence of second primary esophageal cancer was 25.8% for SCC and 3.6% for EAC. DISCUSSION: Post-ER pMM/SM1 esophageal cancer is associated with excellent long-term survival. Surveillance is a reasonable option for many LVI-negative cases, although additional treatment may be considered for selected higher risk patients.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ishihara R, Takahashi H, Abe S, et al. Long-Term Outcomes After Endoscopic Resection for pMM/SM1 Esophageal Cancer: A Multicenter Prospective Cohort Study. Am J Gastroenterol. 2026. PMID: 42754974. doi:10.14309/ajg.0000000000004209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。